Treatment preferences among Japanese patients and physicians for epidermal growth factor receptor-mutant non-small cell lung cancer.

Akito HataSimon FiferKazuo HasegawaEmiko AndoMami Kasahara-KiritaniMichiko TakahashiRobyn OrdmanLili TohAkira Inoue

Published in: Cancer medicine (2024)

Our study revealed Japanese physician and patient preferences in treatment options for EGFR-mutant NSCLC. Compared to the strong preference for a more efficacious drug, the preference of oral versus intravenous revealed a smaller impact.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
primary care
small cell lung cancer
single cell
emergency department
wild type
case report
high dose
decision making
adverse drug
combination therapy